|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PSEN1 binding protein glycogen synthase kinase-3 beta (GSK-3 beta) has been considered as a key protein in AD pathogenesis since GSK-3 beta phosphorylates tau and hyperphosphorylated tau is a main component of neurofibrillary tangles associated to AD.
|
10754226 |
2000 |
|
Alzheimer's Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Glycogen synthase kinase 3 beta (GSK3 beta) phosphorylates the microtubule associated protein tau at sites that are aberrantly phosphorylated in AD.
|
11326302 |
2001 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Main genes involved in AD include mutational loci (APP, PS1, PS2, TAU) and multiple susceptibility loci (APOE, A2M, AACT, LRP1, IL1A, TNF, ACE, BACE, BCHE, CST3, MTHFR, GSK3B, NOS) distributed across the human genome.
|
12369958 |
2002 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
LHGDN |
GSK3beta signalling: casting a wide net in Alzheimer's disease.
|
12566926 |
2003 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sarkosyl-insoluble fractions of the hippocampus were enriched in p38-P and GSK-3 beta-P in Alzheimer's disease (AD) cases, processed in parallel for comparative purposes, but not in the P310L mutation.
|
14757934 |
2003 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
|
15555766 |
2005 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
LHGDN |
Intracellular domains of amyloid precursor-like protein 2 interact with CP2 transcription factor in the nucleus and induce glycogen synthase kinase-3beta expression.
|
16645641 |
2007 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
GSK3beta activity modifies the localization and function of presenilin 1.
|
17389597 |
2007 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
CTD_human |
Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden.
|
17409235 |
2007 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Association of GSK3B with Alzheimer disease and frontotemporal dementia.
|
18852354 |
2008 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Consistent interaction between GSK3B and MAPT genes in three late-onset AD cohorts was observed, with the GSK3B haplotype (T-T) significantly increasing the risk for AD in individuals with at least one H2 haplotype (odds ratio, 1.68-2.33; p = 0.005-0.036).
|
18991351 |
2008 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The relationship between β-amyloid (Aβ) and tau is not fully understood, though it is proposed that in the pathogenesis of Alzheimer's disease (AD) Aβ accumulation precedes and promotes tau hyperphosphorylation via activation of glycogen synthase kinase-3beta (GSK-3β).
|
21181298 |
2011 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The study aims to investigate the effect of Curcumin on the expression of GSK-3β, β-catenin and CyclinD1 in vitro, which are tightly correlated with Wnt/β-catenin signaling pathway, and also to explore the mechanisms, which will provide a novel therapeutic intervention for treatment of Alzheimer's disease.
|
21352912 |
2011 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
A low dose infusion of insulin suppresses APP, presenilin-1, presenilin-2, and glycogen synthase kinase-3β, key proteins involved in the pathogenesis of Alzheimer's disease, in parallel with exerting its other antiinflammatory effects.
|
21411544 |
2011 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The minor allele (T) of the promoter rs334558 within GSK3B was associated with an increased risk of LOAD (odds ratios/OR=1.381, P=0.006), T carriers may be easier to develop AD (P=0.002, power=0.92).
|
21443865 |
2011 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
At 11 months of age, large and progressive increases in p-Tau in transgenic mice, hyperphosphorylated at sites reminiscent of Alzheimer's disease, were noted, along with elevated levels of α-synuclein and glycogen synthase kinase 3β phosphorylated at Tyr216 (p-GSK-3β), a major kinase involved in the hyperphosphorylation of Tau.
|
21453448 |
2011 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase also known as tau protein kinase I, has been implicated in the pathogenic conditions of Alzheimer's disease.
|
21561378 |
2011 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Whereas a decrease of calcium/calmodulin-dependent protein kinase II was observed in 3 × Tg-AD/Fat-1 mice (-039%, p < 0.05), altered tau phosphorylation could not be related to changes in glycogen synthase kinase 3β, cyclin-dependent kinase 5, or protein phosphatase type 2A enzymatic activity.
|
21914946 |
2011 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The prolyl isomerase Pin1 and glycogen synthase kinase-3β (GSK3β) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD.
|
22184106 |
2012 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, little is known about the potential role of the GSK-3β rs334558 polymorphism, which has been associated with amnestic mild cognitive impairment (aMCI), which is itself associated with a high risk of AD.
|
22785398 |
2012 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
GSK3β (glycogen synthase kinase 3β) is a ubiquitous kinase that plays a key role in multiple intracellular signalling pathways, and increased GSK3β activity is implicated in disorders ranging from cancer to Alzheimer's disease.
|
22849606 |
2012 |
|
Alzheimer's Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
We conclude that lymphocytes from young, non-demented persons carrying the ApoE 4/4 genotype show molecular changes that are involved in specific processes associated with the pathophysiology of AD such as increased phosphorylation of tau or increased expression of stress-related proteins like calcineurin, GSK3β, or RCAN1.
|
22914590 |
2013 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tau, a microtubule-associated protein and substrate for GSK3β, has been implicated in the pathogenesis of tauopathies such as Alzheimer's disease.
|
22922102 |
2012 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In experiments with cultured HEK293T cells, we show here that GSK3β stabilizes synaptic acetylcholinesterase (AChE-S), a critical component of AD development.
|
22944069 |
2013 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
CTD_human |
Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3β.
|
22944069 |
2013 |